A randomised, open, placebo controlled 5 way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).

Trial Profile

A randomised, open, placebo controlled 5 way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs GSK 256066 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 08 Nov 2007 Status changed from recruiting to completed.
    • 06 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top